Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Autologous transplantation and management of younger patients with mantle cell lymphoma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Should immunologic strategies be incorporated into frontline ALL therapy?

    Research output: Contribution to journalReviewResearchpeer-review

  1. Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Mantle cell lymphoma is traditionally conceived as one of the NHL subtypes with the worst prognosis and incurable. In responders to frontline induction with CHOP-like chemotherapy autologous stem cell transplantation (ASCT) is proven superior to interferon maintenance, but does not lead to long-term disease control. The efficacy of CHOP as induction therapy before ASCT in MCL is questioned and there is now evidence that as pretreatment before ASCT, AraC + rituximab leads to deeper remission and prolongs progression-free survival compared to rituximab + CHOP. The treatment goal of complete clinical and molecular remission in younger patients with MCL, is now within reach, based on an integrated approach of intensive AraC containing immunochemotherapy with or without subsequent ASCT, and post-treatment maintenance with rituximab or lenalidomide are now being investigated. Such an integrated approach might lead to a shift of paradigm of MCL from an incurable to a curable lymphoma.
Original languageEnglish
JournalBest Practice & Research: Clinical Haematology
Volume25
Issue number2
Pages (from-to)211-20
Number of pages10
ISSN1521-6926
DOIs
Publication statusPublished - 2012

ID: 36545725